Celebrating the Breakthroughs Shaping the Future of Canine Health. Meet the 2025 Canine Health Discovery Award Finalists.

00790: MicroRNA Profiling and MicroRNA-Based Treatment of Canine Cancers

Grant Status: Closed Grant Amount: $94,290.22 William C Kisseberth, DVM, PhD; Ohio State University April 1, 2007 – December 31, 2012 Sponsor(s): American Shetland Sheepdog Association, Estate of Dr. Judith Musladin, Golden Retriever Foundation, Scottish Terrier Club of America, Westie Foundation of America, Inc. Breed(s): -All Dogs Research Program Area: Oncology Donate to Support this […]

00978-A: Isolation of the Canine Telomerase Reverse Transcriptase (TERT) Subunit and Generation of Dominant-Negative Mutants for Telomerase Inhibition

Cancer remains one of the leading causes of death in older dogs. Although surgical techniques, chemotherapy and radiation therapy have been refined over the past 30 years, for many types of cancer, survival rates remain low. Therefore, research has focused on identifying new ways to treat cancer, particularly focused on molecules and enzymes specifically produced […]

00349: Genetic Epidemiology of Cancer in the Golden Retriever

We have collected pedigrees from Golden Retrievers with cancer and constructed a large pedigree map of the affected dogs. As reported in the 1998 GRCA National Health Survey, the most common tumors have been lymphoma and hemangiosarcoma as well as other soft tissue sarcomas. These were aggressive cancers and many occurred at a young age. […]

02244-A: Beyond Peto’s Paradox with the Geriatric Peromyscus

A Collaborative Grant between Triangle Center for Evolutionary Medicine (TriCEM) and AKC Canine Health Foundation (CHF) Cancer is a heterogeneous or widely divergent collection of diseases with a similarly wide variety of outcomes, natural histories and responses to therapy. While new medical and genomic data have shed light on the molecular mechanisms causing cancer, why […]

01426: Personalized Medicine for the Treatment of Canine Mast Cell Tumors

While surgery remains the mainstay of treatment for canine mast cell tumors (MCT), surgery alone is not curative in some cases, and not possible in other cases. Medical therapy remains an important component of MCT therapy. New drugs that affect signaling through the KIT growth factor receptor are showing considerable promise for the treatment of […]

03019: Evaluation of a Targeted Anti αvβ3 Integrin Near-InfraRed (NIR-) Dye for Controlled Resection of Naturally Occurring Soft Tissue Sarcomas in Dogs

Soft tissue sarcomas are among the most common neoplasias of the skin and underlying tissue encountered in dogs. While they rarely spread to other organs, they tend to invade the surrounding tissues and grow unpredictably. Unfortunately, the surgeon cannot delineate these extensions by vision or touch, making it practically impossible to determine the true tumor […]

02636-A: Development of RNA in-situ Hybridization to Identify T Regulatory Cells and their Function within the Tumor Microenvironment of Canine Oral Malignant Melanoma

Oral malignant melanomas (OMM) in dogs have a high potential to metastasize or spread. While OMM is responsive to immunotherapy, responses are varied and difficult to predict, and only a subset of patients respond to immunotherapy. Therefore, it is vital to identify dogs with the best chance of responding to immunotherapy, understand which dogs may […]

01689-A: Increasing the Effectiveness of Radiation Therapy in Treatment of Mast Cell Tumors

Canine mast cell tumors are the most common cutaneous malignant tumors in dogs. Histologic grades, I, II, and III, provide very useful information because they are indicative of a patient’s prognosis. Treatment options depend on negative prognostic factors, but in general surgery and radiation therapy are very effective. Chemotherapy could be applied if the patient […]